Navigation Links
Teva's 'Patient First' Initiative Highlights Struggle Against High Health Care Costs, Reminds Lawmakers of Reform Goals
Date:8/20/2009

Real Americans Share Experiences, Common Need for Patient-Centric Reform

WASHINGTON, Aug. 20 /PRNewswire-USNewswire/ -- Teva Pharmaceuticals USA, the world's leading generic pharmaceutical company, today announced the start of its "Patient First" project as part of the Year of Affordable Healthcare campaign. The initiative, available at: www.yearofaffordablehealth.com/patients, features a first-hand perspective of everyday Americans as they struggle with the enormous and sometimes insurmountable expense of paying for their prescription medicines.

The Patient First initiative features compelling, real-life stories like that of Rob Day, a father of two from Port Huron, Michigan. At age 19, Rob was diagnosed with Paroxysmal Nocturnal Hemoglobinuria (PNH), an extremely rare blood disorder. As his video and profile demonstrate, Rob has spent half his life waiting for a medicine to treat his rare condition. Now that he finally has it, he can't afford to keep it.

The medicine for his condition, a biologic, is extremely expensive, costing $389,000 a year. Rob knows that he must take this medicine for the rest of his life in order to stay alive but doesn't know how he and his family will continue to be able to afford his care.

An FDA approval pathway for generic biologic drugs that provides real, market-based competition, could yield more affordable versions of these biologic medicines for Rob and millions of other Americans in the years to come. In addition to greater access, the benefit of timely competition will be further incentives for innovative biologic medicines that treat diseases including diabetes, multiple sclerosis, Alzheimer's, Parkinson's, psoriasis and cancer. An approval pathway, like the one supported by the Obama Administration and many members of Congress, would do just that - provide relief to people like Rob while introducing billions of dollars in savings for our healthcare system.

"Rob's story is just one of a number of Patient First stories that chronicle the struggles of patients across America," said Debra Barrett, Senior Vice President of Teva Pharmaceuticals USA. "The common thread is the hope for meaningful health care reform that provides relief to those that need it most. Their stories should remind Congress and the White House of what this debate is all about."

To learn more about Rob's story, and other like his, visit the Patient First initiative on-line at: www.yearofaffordablehealth.com/patients

Teva's Year of Affordable Healthcare is a nationwide campaign to recognize the important role that generic drugs play in providing competitive and more affordable healthcare. In addition, the campaign calls upon federal legislators to enact further reforms, including passage of a competitive regulatory approval pathway for generic biologics to increase American access to affordable and lifesaving medicines.

Individuals and organizations can to lend their voices to the Patient First initiative by contacting the Year of Affordable Healthcare campaign at info@yearofaffordablehealth.com

About the Year of Affordable Healthcare

The Year of Affordable Healthcare campaign (www.yearofaffordablehealth.com) is a nationwide call for increased access to affordable healthcare for American citizens. The program coincides with the 25th anniversary of the landmark Hatch-Waxman Act, which created the modern generic pharmaceutical industry and has saved billions of healthcare dollars. For more information, additional videos and details on upcoming events, please visit the Year of Affordable Healthcare Campaign website at: www.yearofaffordablehealth.com.

About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.

Media Contact: Denise Bradley

Phone: (215) 591-8974

E-mail: Denise.Bradley@tevausa.com


'/>"/>
SOURCE Teva Pharmaceuticals USA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Newer Drug Beats Tamoxifen for Older Breast Cancer Patients
2. Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
3. Tumor size and level of visceral pleura invasion can impact survival of NSCLC patients
4. Study shows carvedilol is effective in preventing variceal bleeding in cirrhotic patients
5. Laurence Barsh, DMD, Founder of Snoring Isn't Sexy, LLC Emphasizes Need to Evaluate and Treat Sleep Patients
6. Iterative reconstruction technique significantly reduces patient radiation dose during CT scans
7. Palliative care intervention for patients with advanced cancer provides quality of life benefits
8. Detroit Clinic Owner and Patient Recruiter Plead Guilty in $15 Million Fraud Scheme
9. Uninsured Patients to Receive Free Surgeries, Procedures
10. Free Compirion Bed Flow Webinar Helps Improve Patient Flow From ED to Inpatient Units
11. Identification Systems Group Pledges Support for Standardized Patient Health Identification Cards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s ... Sunday, with sunny skies, a light breeze and temperatures in the 60s. Over 400 ... 5k Run and Walk and 1-mile walk were held to increase awareness about ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton ... $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition —as ... People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making them ...
(Date:4/29/2016)... ... ... type of skin cancer. Although only about 1 percent of skin cancer cases are melanoma, ... are expected to die of melanoma this year. The risk increases with age, and while ... diagnosed cancers in young women. A recent breakthrough in genetic studies may give doctors the ...
(Date:4/29/2016)... Grants Pass, OR (PRWEB) , ... April 29, 2016 , ... ... nutritionists suggest dinner as the meal to miss. That was among the many new ... True Nutrition, on a recent Sharon Kleyne Hour® Power of Water® radio show. Bonny ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... media enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, ... as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/29/2016)... -- Automation is one of the best ... growing demands for productivity in speed, accuracy, throughput and ... already adept of a wide range of functions that ... Instrumentation continues to evolve, and is poised to tackle ... years ago. Originally used mostly by the big pharmaceutical ...
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
Breaking Medicine Technology: